Aptorum Group Ltd Class A - Asset Resilience Ratio
Aptorum Group Ltd Class A (APM) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Aptorum Group Ltd Class A (APM) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2023)
This chart shows how Aptorum Group Ltd Class A's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see APM total asset value.
Liquid Assets Composition Over Time
This chart breaks down Aptorum Group Ltd Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore APM long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Aptorum Group Ltd Class A maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Aptorum Group Ltd Class A Industry Peers by Asset Resilience Ratio
Compare Aptorum Group Ltd Class A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
Annual Asset Resilience Ratio for Aptorum Group Ltd Class A (2017–2023)
The table below shows the annual Asset Resilience Ratio data for Aptorum Group Ltd Class A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $20.64 Million | -- |
| 2022-12-31 | 0.49% | $102.48K | $20.87 Million | -0.59pp |
| 2021-12-31 | 1.08% | $236.62K | $21.91 Million | -63.09pp |
| 2020-12-31 | 64.17% | $28.38 Million | $44.23 Million | +59.74pp |
| 2019-12-31 | 4.44% | $1.06 Million | $23.95 Million | +2.19pp |
| 2018-12-31 | 2.25% | $1.01 Million | $45.07 Million | -4.00pp |
| 2017-12-31 | 6.25% | $1.97 Million | $31.56 Million | -- |
About Aptorum Group Ltd Class A
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small mol… Read more